Circular Genomics Unveils Its CircPATH™ Platform Following Landmark Nature Medicine Study Demonstrating Breakthrough Performance in Early Detection of Alzheimer's Disease
PR Newswire
SAN DIEGO, July 2, 2026
Blood-Based Circular RNA Biomarkers Outperform Gold-Standard Tests, Enable Preclinical Risk Stratification Years Before Symptom Onset, and Open New Era in Precision NeurologyHighlights of Circular Genomics' Alzheimer's assays: validated across nearly 2,400 individuals in three independent cohortsAchieved AUC 0.945 for detecting AD in patients with clinical symptomsAchieved AUC 0.870 for predicting the development of AD in patients without clinical symptoms61% stronger predictive power for progression to symptomatic AD than pTau217 only, enabling true preclinical risk stratification.Capture multi‑pathway AD biology—including amyloid, tau, synaptic dysfunction, neuroinflammation, and APP modulation—through a single blood‑based circRNA signature.SAN DIEGO, July 2, 2026 /PRNewswire/ -- Circular Genomics today announced the launch of CircPATH™, the company's proprietary circular RNA discovery and validation engine, following the publication of landmark findings in Nature Medicine demonstrating that blood-based circular RNA (circRNA) biomarkers can predict Alzheimer's disease (AD) progression with unprecedented accuracy. The study, led by Dr. Carlos Cruchaga at Washington University in St. Louis, represents the first demonstration that circRNAs can predict progression to symptomatic AD and outperform existing gold-standard biomarkers. CircPATH™ serves as the technological backbone powering all of Circular Genomics' future diagnostic product offerings, translating novel RNA biology into clinically actionable tools that promise to transform how neurodegenerative diseases are detected, monitored, and treated.
